News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • SanDisk will replace Atlassian in the Nasdaq-100 effective April 20, prompting likely passive fund flows into SanDisk and out of Atlassian.
  • Rep. Eric Swalwell denies sexual assault claims as endorsements are withdrawn and Democrats urge him to end his California governor campaign.
  • Analysts warn the MATCH Act's planned export controls could severely limit China's advanced chipmaking and disrupt global semiconductor supply chains.
  • Iran says formal ceasefire talks can't start until U.S. honors Lebanon and sanctions commitments, stalling Islamabad diplomacy and raising regional risk.
  • A federal judge issued a temporary restraining order pausing Arizona's indictment of Kalshi after the CFTC intervened, highlighting federal-state regulatory friction.
  • Third Point abandoned its proxy fight and sold its entire stake in CoStar, removing activist pressure on the real estate data firm.
  • DHS ordered furloughed employees to return to duty after a White House emergency order authorized back pay amid the prolonged partial shutdown.

Latest Articles

ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile

ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile

ORIC Pharmaceuticals announced the selection of 400 mg once daily rinzimetostat (ORIC-944) in combination with darolutamide as the recommended Phase 3 dose (RP3D) for the Himalayas-1 global Phase 3 registrational trial in post-abiraterone metastatic castration-resistant prostate cancer (mCRPC). Phase 1b data show favorable safety and promising effi…

TOMI Environmental Solutions, Inc. Reports Full Year 2025 Financial Results and Outlines Growth Initiatives

TOMI Environmental Solutions, Inc. Reports Full Year 2025 Financial Results and Outlines Growth Initiatives

TOMI Environmental Solutions, Inc. announced its financial results for the year ended December 31, 2025. Despite a 27% decline in net sales due primarily to deferred capital expenditures amid economic uncertainty, the company improved its operating loss compared to 2024. TOMI continued to expand its global market presence, secured notable governmen…

Barfresh Announces Fourth Quarter and Full Year 2025 Results

Barfresh Announces Fourth Quarter and Full Year 2025 Results

Barfresh Food Group Inc. announced record revenue for 2025 of $14.2 million, driven by the acquisition of Arps Dairy and expanded school penetration. The company provided optimistic 2026 guidance with expected revenue between $28 million and $32 million, reflecting nearly 100% growth year-over-year. Barfresh secured $7.5 million in convertible note…

Rigetti Announces Novera QPU Sale to the University of Saskatchewan

Rigetti Announces Novera QPU Sale to the University of Saskatchewan

Rigetti Computing announced the sale and shipment of its 9-qubit Novera quantum processing unit (QPU) to the University of Saskatchewan, marking the establishment of USask's first quantum computing system. The system will be managed by the university's Centre for Quantum Topology and its Applications and aims to support innovative research in quant…

nCino Reports Fourth Quarter and Fiscal Year 2026 Financial Results

nCino Reports Fourth Quarter and Fiscal Year 2026 Financial Results

nCino, Inc., a leading provider of intelligent banking solutions, reported strong financial results for the fourth quarter and fiscal year 2026, exceeding all financial guidance metrics. The company achieved record annual contract value (ACV) of $602.4 million, up 17% year-over-year, and a fiscal 2026 ACV net retention rate of 112%. Total revenues …

Brookfield Business Corporation Completes 2025 Annual Filings

Brookfield Business Corporation Completes 2025 Annual Filings

Brookfield Business Corporation has filed its 2025 annual report with the SEC and Canadian securities authorities, including audited financial statements. The company finalized a corporate simplification by exchanging various partnership units for newly issued Class A shares, which will begin trading on the NYSE and TSX under the ticker BBUC starti…

Ellomay Capital Reports Publication of Financial Statements of Dorad Energy Ltd. as of and for the Year Ended December 31, 2025

Ellomay Capital Reports Publication of Financial Statements of Dorad Energy Ltd. as of and for the Year Ended December 31, 2025

Ellomay Capital Ltd. has published the financial statements of Dorad Energy Ltd. for the year ended December 31, 2025. Ellomay holds an indirect 16.9% stake in Dorad through Ellomay Luzon Energy. Dorad reported revenues of approximately NIS 2.65 billion and an operating profit of NIS 385 million for 2025. The results were impacted by seasonal elect…

Data Storage Corporation Postpones 2025 Fiscal Year Conference Call

Data Storage Corporation Postpones 2025 Fiscal Year Conference Call

Data Storage Corporation announced the postponement of its fiscal year 2025 investor conference call to allow more time to complete its year-end audit. The audit complexity stems from significant transactions including the sale of its CloudFirst subsidiary, warrant settlements, and a tender offer. A new date for the earnings call will be announced …

HeartCore Reports Full Year 2025 Results

HeartCore Reports Full Year 2025 Results

HeartCore Enterprises, Inc., a Tokyo-based IPO consulting services company listed on Nasdaq (HTCR), announced its full year 2025 results. The company reported revenues of $9.0 million, gross profit of $3.2 million, and net income of $5.5 million compared to a net loss last year. The positive net income was primarily due to gains from the divestitur…

Cognition Therapeutics CEO Issues Letter to Shareholders

Cognition Therapeutics CEO Issues Letter to Shareholders

Cognition Therapeutics announced progress in developing their lead candidate, Zervimesine (CT1812), for neurodegenerative diseases. Positive Phase 2 SHIMMER trial results support advancing the drug to late-stage trials for dementia with Lewy bodies (DLB) psychosis. The ongoing fully funded Phase 2 START trial in mild cognitive impairment and early …

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

Tarsus Pharmaceuticals has dosed the first participant in its Phase 2 Calliope trial evaluating TP-05 (lotilaner), an investigational oral systemic therapy aimed at preventing Lyme disease by killing infected ticks before transmission. The randomized, placebo-controlled trial will enroll approximately 700 adults at risk across endemic U.S. regions,…

BIO-key Reports 2025 Results and Substantially Improved Cash Position, Supporting Expected Strong Growth in 2026; Investor Call Today at 10am ET

BIO-key Reports 2025 Results and Substantially Improved Cash Position, Supporting Expected Strong Growth in 2026; Investor Call Today at 10am ET

BIO-key International announced its 2025 financial results showing $6.1M revenue with a 12% decline from 2024 due to strategic shifts in the EMEA region. The company improved its cash position to $2.7M and expects solid revenue growth and improved profitability in 2026, driven by increased demand in foreign military, defense, financial sectors, and…

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

PolyPid Ltd. has begun submitting its New Drug Application for D-PLEX100 to the FDA under a rolling review process, targeting approval by Q2 2026. The lead product, designed to prevent surgical site infections after colorectal surgery, demonstrated significant efficacy in Phase 3 trials and has received FDA Breakthrough Therapy Designation. The com…